Foundation News

Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel disease (IBD), which may affect as many as 1 in 100 Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.

The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians.

Diversigen Inc. is pleased to announce that the company has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform.

The Crohn’s & Colitis Foundation announced that it received a $5 million pledge from the Litwin family to fund novel, high-risk/high-reward research ideas in the early stage of exploration that could advance the field of inflammatory bowel diseases (IBD) research.

The Crohn’s & Colitis Foundation (the Foundation) celebrates the visionary academic and industry scientists, The Leona M. and Harry B. Helmsley Charitable Trust, IBD patients, and Foundation staff who are partnering to create and sustain IBD Plexus®, a first-of-its-kind research information exchange platform designed to centralize data and biosamples from diverse research studies. The powerful new initiative is designed to advance our understanding of Crohn’s disease and ulcerative colitis, or inflammatory bowel diseases (IBD), and significantly accelerate research driving toward precision medicine and cures for IBD.